APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

20 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

27 11 2024 16:10:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Reports Third Quarter 2024 Financial Results

07 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

18 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics to Participate in Upcoming Investor Conferences

04 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Reports Second Quarter 2024 Financial Results

07 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Added to Russell 3000® Index

01 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2024 Financial Results

09 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference

07 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

15 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

04 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

28 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

06 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Announces $100 Million Private Placement

28 2 2024 08:05:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia

28 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

15 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

04 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia

03 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Applied Therapeutics Reports Third Quarter 2023 Financial Results

09 11 2023 07:30:54 提供 Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

02 11 2023 07:00:00 提供 Nasdaq GlobeNewswire